NCT01541072 - Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

September 30, 2014

Conditions

Non Hodgkin Lymphoma

Interventions

DRUG

Pegfilgrastim

Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation

DRUG

Filgrastim

Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils \>= 0.5 G/L)

Trial Locations (2)

63000

CHU Clermont-Ferrand, Hôpital d'Estaing, Clermont-Ferrand

Unknown

Centre Leon Berard, Lyon